Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)
Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Metastases, Neoplasm
About this trial
This is an interventional treatment trial for Brain Neoplasms focused on measuring Brain Neoplasms/radiotherapy, Neoplasms/complications/prevention & control,, Neuropsychological Tests,, Metalloporphyrins/therapeutic use,, Combined Modality Therapy,, Drug therapy,, Quality of Life,, Cranial Irradiation,, Radiotherapy/Targeted,, Prospective Studies,, Neoplasm Recurrence/Local,, Treatment Outcome, Brain metastases, Brain Neoplasms/secondary, Non-small cell lung cancer
Eligibility Criteria
Inclusion Criteria: Adults (≥18 years old) with radiologically proven parenchymal brain metastases from histologically confirmed non-small cell lung cancer; KPS score of ≥70; Each patient must sign a study-specific Informed Consent form Exclusion Criteria: Liver metastases; Extracranial metastases in two or more organs; Known leptomeningeal metastases or subarachnoid spread of tumor; Prior whole brain radiation; Plan to use radiosurgery or radiation boost after completion of WBRT; Planned chemotherapy during study treatment (prior and subsequent chemotherapy is allowed); Prior total resection of a single brain metastasis; Laboratory values as follows: LDH > 1.3 x upper limit of normal (ULN); ANC < 1500 /mm³; Platelets < 50,000 /mm³; Creatinine > 2.0 mg/dL; AST or ALT > 2 x ULN; Total bilirubin > 2 x ULN; Women who are pregnant or lactating